*3.2. Patient Demographics*

Patient demographics according to the cutoff values of SUVmax, MTV, and TLG on 18F-FDG uptake are listed in Table 1. In the 17 patients harboring epidermal growth factor receptor (*EGFR)* mutation, deletion 19 and L858R were observed in 11 and 6 patients, respectively. High TLG and SUVmax on 18F-FDG uptake were significantly associated with smoking history. The objective response rate and disease control rate were 36.6% [95% confidence internal (CI); 26.2%–47.0%] and 65.9% [95%CI; 55.6%–76.1%]. No significant difference in the response to ICI was observed according to the degree of SUVmax, MTV, and TLG on 18F-FDG uptake. The median time from the date of 18F-FDG-PET scan to the initiation of anti-PD-1 antibodies was 18 days (range, 1–107 days). Next, we analyzed different incidences of immune-related adverse events (irAEs) according to the degree of SUVmax, MTV, and TLG on 18F-FDG uptake and TB. The frequency of any irAE was significantly higher in patients with low values of SUVmax, MTV, and TLG on PET than in those with high values, but not for TB (Table S1, online only). The incidence of grade 3 or 4 irAEs exhibited no close correlation with the degree of 18F-FDG uptake on PET and TB.

**Table 1.** Patient's demographics according to the assessment of FDG uptake.


Abbreviations: TLG, total lesion glycolysis; MTV, metabolic tumor volume; SUVmax, the maximum of standardized uptake value; AC, adenocarcinoma; Non-AC, non-adenocarcinoma; EGFR, epidermal growth factor receptor; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ICI, immune checkpoint inhibitor. #, because of 6 patients with no measurable lesion, 82 patients were analyzed according to the uptake of FDG; Bold character shows statistically significance.
